Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica Coutre, S., Tedeschi, A., Robak, T., Barr, P. M., Owen, C., Bairey, O., Burger, J., Zhou, C., Styles, L., James, D. F., Kipps, T. J. 2018; 103 (6): e249–e251

View details for PubMedID 29170253